These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17149393)

  • 1. Maculopapular skin rashes associated with high-dose chemotherapy: prevalence and risk factors.
    Wright LG
    Oncol Nurs Forum; 2006 Nov; 33(6):1095-103. PubMed ID: 17149393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnose, assess, and manage infusion reactions.
    Becze E
    ONS Connect; 2010 Jul; 25(7):12-3. PubMed ID: 20669809
    [No Abstract]   [Full Text] [Related]  

  • 3. Carboplatin hypersensitivity reactions.
    Winkeljohn D; Polovich M
    Clin J Oncol Nurs; 2006 Oct; 10(5):595-8. PubMed ID: 17063613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy and cutaneous toxicities: implications for oncology nurses.
    Viale PH
    Semin Oncol Nurs; 2006 Aug; 22(3):144-51. PubMed ID: 16893743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk.
    Patt DA; Duan Z; Fang S; Hortobagyi GN; Giordano SH
    J Clin Oncol; 2007 Sep; 25(25):3871-6. PubMed ID: 17664457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
    Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
    J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous immunoglobulin administration: an evaluation of vital sign monitoring.
    Camp-Sorrell D; Wujcik D
    Oncol Nurs Forum; 1994 Apr; 21(3):531-5. PubMed ID: 8052549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia.
    Malfuson JV; Etienne A; Turlure P; de Revel T; Thomas X; Contentin N; Terré C; Rigaudeau S; Bordessoule D; Vey N; Gardin C; Dombret H;
    Haematologica; 2008 Dec; 93(12):1806-13. PubMed ID: 18838471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The experience of fatigue in Turkish patients receiving chemotherapy.
    Yurtsever S
    Oncol Nurs Forum; 2007 May; 34(3):721-8. PubMed ID: 17573331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
    Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
    Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment: Implications for oncology nurses.
    Kearney N; Friese C
    Eur J Oncol Nurs; 2008 Feb; 12(1):14-25. PubMed ID: 18291720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxic rash associated with high dose methotrexate therapy.
    Bell R; Sullivan JR; Burdon JG; Sinclair R
    Clin Exp Pharmacol Physiol Suppl; 1979; 5():57-61. PubMed ID: 318498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
    Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
    J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review.
    Kim BH; Bradley T; Tai J; Budman DR
    Oncology; 2009; 76(4):231-8. PubMed ID: 19246947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey.
    Repetto L;
    Crit Rev Oncol Hematol; 2009 Nov; 72(2):170-9. PubMed ID: 19406660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutropenia: state of the knowledge part II.
    Nirenberg A; Parry Bush A; Davis A; Friese CR; Wicklin Gillespie T; Rice RD
    Oncol Nurs Forum; 2006 Nov; 33(6):1202-8. PubMed ID: 17149403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low negative predictive value of skin tests in investigating delayed reactions to radio-contrast media.
    Vernassiere C; Trechot P; Commun N; Schmutz JL; Barbaud A
    Contact Dermatitis; 2004 Jun; 50(6):359-66. PubMed ID: 15274727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience.
    Polyzos A; Tsavaris N; Gogas H; Souglakos J; Vambakas L; Vardakas N; Polyzos K; Tsigris C; Mantas D; Papachristodoulou A; Nikiteas N; Karavokyros JG; Felekouras E; Griniatsos J; Giannopoulos A; Kouraklis G
    Oncology; 2009; 76(1):36-41. PubMed ID: 19033714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.